Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 15/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320957 | 0.86 | ADRA1D (0.41) | ADRA1DADRA1AADRA1BPDE1CELANE | |
| SCHEMBL6313829 | 0.86 | ADRA1D (0.37) | ADRA1DADRA1AADRA1BPDE1CELANE | |
| SCHEMBL6312051 | 0.85 | ALDH1A1 (0.41) | ADRA1DADRA1AADRA1BPDE1CGAA | |
| SCHEMBL6137417 | 0.84 | TSHR (0.36) | ADRA1DADRA1AADRA1BTSHRNPSR1 | |
| SCHEMBL6312377 | 0.84 | TSHR (0.37) | TSHRNPSR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6314072 | 0.84 | ELANE (0.41) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6315050 | 0.82 | ADRA1D (0.49) | ADRA1DADRA1AADRA1BPDE1C | |
| SCHEMBL6314801 | 0.81 | MAPT (0.46) | ADRA1DADRA1AADRA1BTSHRNPSR1 | |
| SCHEMBL6314301 | 0.81 | ABCC9 (0.45) | ADRA1DADRA1AADRA1BPDE1C | |
| SCHEMBL6320926 | 0.81 | PDE1C (0.38) | ADRA1DADRA1AADRA1BPDE1CCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809102-B2 | FOR THERAPY OF PROLIFERATIVE DISEASES, SUCH AS CANCER; TO INTERRUPT MITOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-26 | — | — | US | claimed |
| EP-1373221-A4 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1373221-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | claimed |
| US-20030008888-A1 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | claimed |
| WO-2002079149-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
| US-6900214-B2 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1373223-A4 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373221-A4 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373223-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1373221-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030008888-A1 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2002079169-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002079149-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | ADRA1D 3925/4885ADRA1A 3583/4885ADRA1B 3332/4885 |
| US-20030008888-A1 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | ADRA1D 3767/4885ADRA1A 3570/4885ADRA1B 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.